Literature DB >> 30661045

Hypokalaemic metabolic alkalosis, hypertension and diabetes: what is the link.

Marius Vögelin1, Richard Cathomas2, Niklaus Kamber3, Thomas Fehr1.   

Abstract

Two years after diagnosis of a metastatic neuroendocrine gastrin-secreting tumour and after several cycles of chemotherapy and peptide receptor radionuclide therapy, a 56-year-old woman presented with hypokalaemic metabolic alkalosis, hypertension, leg oedema and new-onset diabetes mellitus. Further investigations revealed renal potassium loss confirmed by a transtubular potassium gradient of 16, fully suppressed serum aldosterone, but instead highly elevated blood levels of morning cortisol and adrenocorticotropic hormone as well as increased urinary excretion of glucocorticoid and mineralocorticoid metabolites. Ruling out other causes, paraneoplastic hypercortisolism was diagnosed. Pharmacological inhibition of the steroid 11β-hydroxylase with metyrapone resulted in complete resolution of metabolic alkalosis, hypokalaemia, hypertension, hyperglycaemia and leg oedema within 1 week. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  diabetes; drugs: endocrine system; endocrine cancer; fluid electrolyte and acid-base disturbances; hypertension

Mesh:

Substances:

Year:  2019        PMID: 30661045      PMCID: PMC6340553          DOI: 10.1136/bcr-2018-227068

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  21 in total

1.  Pitfall of petrosal sinus sampling in a Cushing's syndrome secondary to ectopic adrenocorticotropin-corticotropin releasing hormone (ACTH-CRH) secretion.

Authors:  J Young; C Deneux; M Grino; C Oliver; P Chanson; G Schaison
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

Review 2.  Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome.

Authors:  Eleni Daniel; John D C Newell-Price
Journal:  Eur J Endocrinol       Date:  2015-01-30       Impact factor: 6.664

3.  Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.

Authors:  D C Aron; H Raff; J W Findling
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

4.  ACTH and CRF-producing bronchial carcinoid associated with Cushing's syndrome.

Authors:  A Zárate; K Kovacs; M Flores; C Morán; I Félix
Journal:  Clin Endocrinol (Oxf)       Date:  1986-05       Impact factor: 3.478

5.  Ectopic Cushing's syndrome due to concurrent corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secreted by malignant gastrinoma.

Authors:  S Y Park; Y Rhee; J C Youn; Y N Park; S Lee; D M Kim; S Y Song; S-K Lim
Journal:  Exp Clin Endocrinol Diabetes       Date:  2007-01       Impact factor: 2.949

6.  Nizoral (Ketoconazole): drug safety communication- potentially fatal liver injury, risk of drug interactions, and adrenal gland problems.

Authors: 
Journal:  Clin Infect Dis       Date:  2013-10       Impact factor: 9.079

7.  Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.

Authors:  Dominique Maiter; Marie Bex; Laurent Vroonen; Guy T'Sjoen; Thierry Gil; Camille Banh; Rita Chadarevian
Journal:  Ann Endocrinol (Paris)       Date:  2016-04-07       Impact factor: 2.478

8.  Paraneoplastic Cushing syndrome, case-series and review of the literature.

Authors:  Annelies Deldycke; Christel Haenebalcke; Youri Taes
Journal:  Acta Clin Belg       Date:  2017-09-12       Impact factor: 1.264

9.  Nonpituitary neoplasms and Cushing's syndrome. Ectopic "adrenocorticotropin" produced by nonpituitary neoplasms as a cause of Cushing's syndrome.

Authors:  G W LIDDLE; D P ISLAND; R L NEY; W E NICHOLSON; N SHIMIZU
Journal:  Arch Intern Med       Date:  1963-04

10.  Ectopic adrenocorticotropic hormone syndrome in a case of duodenal neuroendocrine tumor presenting with liver metastasis.

Authors:  J Khare; S Daga; S Nalla; P Deb
Journal:  J Postgrad Med       Date:  2018 Jan-Mar       Impact factor: 1.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.